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Carbon-based nanomaterials including carbon nanotubes, graphene oxide, fullerenes and nanodiamonds are potential candidates for various
applications in medicine such as drug delivery and imaging. However, the successful translation of nanomaterials for biomedical applications is
predicated on a detailed understanding of the biological interactions of these materials. Indeed, the potential impact of the so-called bio-corona
of proteins, lipids, and other biomolecules on the fate of nanomaterials in the body should not be ignored. Enzymatic degradation of carbon-
based nanomaterials by immune-competent cells serves as a special case of bio-corona interactions with important implications for the medical
use of such nanomaterials. In the present review, we highlight emerging biomedical applications of carbon-based nanomaterials. We also
discuss recent studies on nanomaterial ‘coronation’ and how this impacts on biodistribution and targeting along with studies on the enzymatic
degradation of carbon-based nanomaterials, and the role of surface modification of nanomaterials for these biological interactions.
From the Clinical Editor: Advances in technology have produced many carbon-based nanomaterials. These are increasingly being
investigated for the use in diagnostics and therapeutics. Nonetheless, there remains a knowledge gap in terms of the understanding of the
biological interactions of these materials. In this paper, the authors provided a comprehensive review on the recent biomedical applications
and the interactions of various carbon-based nanomaterials.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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opportunities in several areas of medicine including therapeutics,
diagnostics, imaging, and regenerative medicine.1,2 Carbon-based
nanomaterials such as fullerenes, carbon nanotubes, carbon nano-
horns, carbon nanodots, nanodiamonds, and graphene and its
derivatives have unique electronic, optical, thermal, andmechanical
properties and have attracted considerable attention in recent years
in nanomedicine.3-5 Hence, many studies have attempted to exploit
thesematerials for drug delivery or imaging, or both. As pointed out
in a recent editorial, the successful commercialization of nanome-
dicines ultimately depends on demonstrating their superiority over
existing approaches and on documenting their safety.2 Indeed, a
detailed understanding of the biological interactions of nanomater-
ials, not least the interactions with cellular and other components of
the immune system (Figure 1) is important both from an efficacynder theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
on-based nanomaterials: From coronation to degradation. Nanomedicine:
Figure 1. Cellular and extracellular interactions of carbon nanotubes. The
upper panel shows an SEM image of isolated MWCNTs (single arrow) or a
bundle of MWCNTs (two arrows) entering human mesothelial cells.
Reprinted from: Shi X, von dem Bussche A, Hurt RH, Kane AB, Gao H.
Cell entry of one-dimensional nanomaterials occurs by tip recognition and
rotation. Nat Nanotechnol. 2011;6(11):714-9, with permission from Nature
Publishing Group. The lower panel shows a cluster of short-cut SWCNTs
(single arrow) entrapped in chromatin fibers (two arrows) of purified
neutrophil extracellular traps [see Farrera et al6 for further details]. SEM
courtesy of K. Hultenby, Karolinska Institutet.
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of the nanomaterial– accumulation, degradation, and/or excretion–
in the human body.7 To this end, particular attention should be
devoted to the role of adsorbed biomolecules which may confer a
new biological ‘identity’ to nanomaterials,8 and is likely to play an
important role for cellular uptake and in vivo biodistribution
of nanomaterials.9
Detailed accounts of the routes of synthesis and the
physicochemical properties of carbon-based nanomaterials are
beyond the scope of the present review, but a brief introduction is
provided here. Fullerenes are entirely composed of carbon and
have the form of spheres, ellipsoids or tubules. Spherical and
cylindrical fullerenes are also referred to as buckyballs and
buckytubes (or carbon nanotubes), respectively. The first
representative of the buckyball family, referred to as buckmin-
sterfullerene, is composed of 60 carbon atoms (C60) and has the
shape of a truncated icosahedron with 20 hexagons and 12
pentagons and a diameter of approximately 1 nm, thus
resembling a football (in the United States, a soccer ball);
indeed, a picture of a football was included in the very first
publication, and the authors even contemplated the alternative
name, soccerene.10 Iijima is credited with the discovery of
carbon nanotubes (CNTs)11 although some claim that thesestructures (“graphitic carbon needles”) had been observed
decades earlier.12 CNTs are graphitic tubules, which can be
capped with hemifullerenes at the ends, consisting of a single
graphene sheet (single-walled carbon nanotubes, SWCNTs) or
several concentric and nested sheets (multi-walled carbon
nanotubes, MWCNTs). Both types of CNTs have nano-scale
dimensions and display a very high aspect ratio, i.e., the ratio
between the length and the diameter of the material. Hence,
SWCNTs have a diameter of approximately 1 nmand lengths up to
a few microns or more, whereas MWCNTs have diameters of
several tens of nanometers and lengths up to several tens ofmicrons
or more. All of the aforementioned nanomaterials can be related to
a parent material known as graphene consisting of a single
atomically thin sheet of hexagonally bound sp2 carbon atoms.13
For a comprehensive overview of the structural, electronic, and
biological properties and applications of graphene and other 2-D
materials, see Ferrari et al.14 Nanodiamonds represent yet another
class of nanoparticles in the carbon family, with highly versatile
physical and chemical properties.15 They are mainly composed of
carbon sp3 structures in the core, with sp2 and disorder/defect
carbons on the surface, and display single-digit nm sizes.
In the present review, we will highlight emerging biomedical
applications of various carbon-based nanomaterials. We will also
discuss bio-corona formation and the propensity for enzymatic
degradation, especially with regards to CNTs and graphene
oxide (GO), which are the most intensively investigated
carbon-based nanomaterials to date in the field of nanomedicine,
along with fullerenes and nanodiamonds. The impact of surface
modifications, including grafting of polymers, on the biological
interactions of these materials is also highlighted.Biocompatibility of carbon-based nanomaterials
Being small confers advantages in terms of negotiating biological
barriers, which may be desirable, but nanoscale size per se is not
sufficient to qualify as a nanotechnology.16 Carbon-based nanoma-
terials, however, possess intrinsic physicochemical properties that
can potentially be exploited. For instance, CNTs display strong
optical absorption in the near infrared, Raman scattering as well as
photo-acoustic properties that widen the scope of in vivo applications
as they can potentially have bio-imaging and tracing functions
coupled with drug delivery.4 Graphene is another material with
many promising areas of application as a result of its large surface
area and possibility of easy functionalization, providing opportuni-
ties for drug delivery.5 Moreover, its unique mechanical properties
suggest tissue engineering and regenerativemedicine applications.17
Other carbon-based nanomaterials such as fullerenes and nanodia-
monds have also received much attention in recent years, with
emphasis mainly in the area of cancer medicine.4 In the present
review, we will highlight some illustrative, pre-clinical examples
from recent literature.
However, safety first. The potential toxicity of carbon-based
nanomaterials has been the subject of much concern in the past
decade and much skepticism initially surrounded the notion of
using, in particular, CNTs as drug delivery systems due to the fact
that these fiber-like materials were presumed to be biopersistent,
and, therefore, to possess asbestos-like pathogenicity.18-20
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the biocompatibility of CNTs through surface modification of the
materials and has also demonstrated the susceptibility for
enzymatic degradation of these nanomaterials (discussed below).
Indeed, it is important to distinguish potentially harmful CNTs21
from more biocompatible ones. Moreover, there are important
lessons to be learned from these extensive toxicological
investigations.22,23 Categorization or grouping of nanomaterials
according to their risk potential, taking into account indicators of
both hazard and exposure, is needed to identify ‘nanomaterials of
concern’.24 Overall, it is necessary to avoid generalizations about
the toxicity of ‘carbon nanotubes’ or, for that matter, of ‘graphene’,
as these are not single nanomaterials, but classes of nanomaterials
with important differences in terms of their physicochemical
properties (such as, aspect ratio or lateral dimensions, purity,
surface functionalization, and so on) and, hence, in their
toxicological profile. Thus, with careful evaluation of the
biological interactions of each nanomaterial, a more favorable
scenario for their exploitation in medicine presents itself. Of key
importance for any biocompatibility assessment of nanomaterials
is the evaluation of potential effects on the immune system.9
Indeed, the immune system has evolved to protect us from
pathogens and other foreign intrusion. In brief, the immune system
can be divided into the innate and the adaptive (or acquired)
immune system. The innate immune system is composed of
inflammatory cells or ‘sensors’ and soluble ‘mediators’ (i.e.,
complement factors, chemokines, and cytokines).20 It is this arm of
the immune system that nanomaterials first encounter following
either deliberate or accidental (occupational/non-occupational)
exposures. The inflammatory cells encompass macrophages,
professional phagocytic cells that differentiate from monocytes
that migrate from the circulation and extravagate into tissues. The
main functions of monocytes are phagocytosis, antigen presenta-
tion and cytokine production. Functionalized CNTs have been
reported to activate immune-related pathways in monocytes
suggesting that such carbon-based nanomaterials may function
as immunostimulatory agents.25 CNTs were also found to trigger
so-called inflammasome activation in monocytes26 as well as in
primary human monocyte-derived macrophages27 leading to the
secretion of the pro-inflammatory cytokine, interleukin (IL)-1β
[for a review, see Bhattacharya et al20]. In a related study, surface
functionalization of CNTs or carbon nano-onions (CNOs)
attenuated the inflammatory properties of these nanomaterials,
with a reduction in the recruitment of inflammatory neutrophils and
monocytes in vivo and reduced IL-1β production.28 Strategically
located macrophages act as sentinels against foreign materials and
can be divided into various subpopulations based upon their
anatomical location and functional phenotypes. The granulocytes,
including neutrophils, basophils, and eosinophils, also form part of
the innate immune system, along with mast cells, a tissue-resident
granulocytic cell that is closely related to basophils. Natural killer
(NK) cells are a component of the innate immune system which
does not directly attack invading microbes. Instead, these cells
destroy tumor cells or virus-infected cells. The interaction between
immune cells and tumors, and the role of immune cells as sentinels
in eliminating continuously arising transformed cells, are of
particular importance for nanomedicine. Dendritic cells (DCs) are
antigen-presenting cells that serve as a ‘bridge’ between the innateand adaptive arms of the immune system. The adaptive immune
system, in turn, is composed of B cells and T cells, and these cells
are responsible for immunological ‘memory’ which is ‘adaptive’
because it occurs during the lifetime of an individual as an
adaptation to encounters with a specific pathogen. Nanomaterials
have been shown to interact with cells of the innate immune
system, while effects on the adaptive immune system occur, in
most but not all cases, via the innate immune system [see Farrera
and Fadeel9 and Boraschi et al29 for a review]. To give one recent
example,GOwas shown to trigger a typical ‘foreign body’ reaction
in mice upon subcutaneous implantation, with recruitment of
neutrophils, followed by monocytes; these cells secreted a variety
of soluble mediators resulting in the establishment of an
inflammatory microenvironment.30 GO and CNTs have both
been reported to act directly on macrophages and DCs ex vivo and
in animal models.31-33 As we shall discuss in the present review,
the interactions between carbon-based nanomaterials and the
immune system can be reciprocal in the sense that immune-
competent cells such as macrophages and neutrophils can ‘strike
back’ and digest nanomaterials.20
Biomedical applications of carbon-based nanomaterials
Carbon-based nanomaterials display excellent mechanical,
thermal and optical properties making them potentially useful
and attractive in medicine, including for therapeutics and/or
diagnostics, as well as in regenerative medicine. In the following
section, we shall discuss examples of each of these broad areas
beginning with therapeutics, which in turn may be divided into:
carbon-based nanomaterials as drug or gene delivery vehicles, or
carbon-based nanomaterials as drugs per se.
CNTs have been studied intensively as drug carriers, with
doxorubicin being the most common model drug [see Chen et al4
for a recent review]. To this end, drugs may be loaded onto CNTs
through noncovalent interactions, eg., π-π stacking as shown for
doxorubicin,4 although covalent binding has also been explored
for hydrophilic drugs.34 In the latter study, the authors covalently
attached not only the drug, cisplatin but also the targeting ligand,
epidermal growth factor (EGF), and demonstrated that these
targeted vectors were selectively taken up by head and neck
squamous carcinoma cells overexpressing EGF receptors.34
Moreover, regression of tumor growth was rapid in mice treated
with targeted SWCNT-cisplatin conjugates relative to the
non-targeted ones. CNTs may also serve as multi-functional
devices for selective cancer cell destruction, by virtue of their
intrinsic physicochemical properties. For instance, Kam et al35
reported that SWCNTs can be deployed for targeted delivery of
oligonucleotides to cancer cells with near-infrared light-
mediated killing of cancer cells due to the excessive local
heating of the CNTs.
CNTs are known to interact with DNA and much interest has
been devoted to the potential use of CNTs for gene delivery or
delivery of small interfering RNA (siRNA). Some authors have
claimed a passive, “needle-like” mechanism of cellular entry for
CNTs,36 which could be exploited for gene delivery, if proven to
be specific for the intended target cells. In this context, the
formation of a so-called bio-corona on the surface of the CNTs
and its potential impact on cellular recognition and uptake needs
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provided evidence for efficient delivery of siRNA directly to the
CNS through stereotactic administration of MWCNTs, resulting
in neuroprotection in mice and rats. We recently demonstrated
that PEG-modified SWCNTs can be deployed as carriers for
intra-articular delivery of antisense oligonucleotides to chon-
drocytes in mice without affecting cartilage homeostasis or
eliciting systemic side-effects.38 In another recent study, we
developed a novel strategy for delivery of microRNAs to
endothelial cells to regulate angiogenesis, using polymer
functionalized MWCNTs (submitted for publication). We
found that endothelial cells displayed efficient uptake of
miR-503 following administration of miR-503 bound to the
functionalized CNTs, and a decrease of vessel formation was
observed in a mouse model of angiogenesis. Moreover, the
polymer-coated CNTs displayed a reduced toxicity when
compared to the pristine CNTs.
Graphene is another promising material for drug delivery.
Indeed, as pointed out by Novoselov et al,39 graphene derivatives
can solubilize and bind drug molecules as a result of their large
surface area and delocalized π electrons, and thus have the
potential to act as drug delivery vehicles if sufficiently high drug
loading and suitable in vivo drug distribution and release profiles
can be achieved. In one of the earliest studies on the potential
biomedical uses of graphene, Yang et al40 showed that intravenous
administration of PEG-modified GO labeled with a near-infrared
fluorescence dye, but not carrying any drug, displayed significant
passive tumor targeting in several mouse xenograft models and
relatively low retention in the reticuloendothelial system. The
authors utilized the strong optical absorbance of the nanomaterial
in the near-infrared region for in vivo photothermal therapy,
achieving efficient tumor ablation. Moreover, a reduced GO-iron
oxide nanoparticle complex functionalized with PEGwas found to
display excellent physiological stability, strong near-infrared
optical absorbance, and superparamagnetic properties.41 Using
this novel theranostic probe, in vivo tri-modal fluorescence,
photoacoustic, and magnetic resonance imaging was carried out,
uncovering high passive tumor targeting, and this was further used
for photothermal ablation of tumors in mice.41 Furthermore,
loading of doxorubicin onto the PEG-modified GO-iron oxide
nanoparticle complex enabled magnetically targeted drug
delivery.42 In the latter study, magnetic resonance imaging of
breast tumor-bearing mice was also demonstrated using GO–iron
oxide NP–PEG as contrast agent. In a recent study, doxorubicin
was chemically conjugated to polymer (i.e., PEI-PEG) grafted GO
via a matrix metalloproteinase 2 (MMP2)-cleavable peptide
linker.43 MMPs are a family of enzymes predominantly secreted
by tumor cells. Under normal conditions the intrinsic fluores-
cence property of doxorubicin is quenched by GO; upon
incubation with MMP2, the peptide is cleaved thereby
permitting the unloading of doxorubicin for tumor cell killing
and concurrent fluorescence recovery of doxorubicin for tumor
cell imaging,43 making this a versatile system, if not
‘theranostic’ in the conventional sense. Further studies are
warranted to evaluate this approach using relevant in vivo tumor
models, and to ascertain whether the adsorption of biomolecules
leading to a bio-corona (discussed below) would obscure the
peptide linker.Fullerenes, especially C60, have received widespread atten-
tion as drug and gene delivery vehicles.44 In one pertinent
example, gene delivery in vivo using water-soluble fullerenes
was demonstrated.45 The in vivo biodistribution of the full-
erene-DNA complexes and a lipid-based system (Lipofectin)
showed similar patterns; however, levels of reporter gene
expression varied insofar as the fullerene-based system achieved
up to 10-fold higher gene expression than Lipofectin in the liver
and spleen, and no gene expression in the lung. The differences
in organ selectivity of the fullerene-based system could be
exploited for diseases of the liver and spleen.45 Furthermore, as
proof-of-principle, the authors demonstrated that the delivery of
an insulin gene using fullerenes increased plasma insulin levels
and reduced blood glucose concentrations in mice.
The metallofullerenol nanoparticles are fullerene derivatives
consisting of a metal atom inside a fullerene cage and are
currently investigated for their unique mechanical, thermal and
electrochemical properties. In particular, gadolinium (Gd) based
metallofullerenes are developed as innovative contrast agents,
and may also act as anti-cancer agents.46 For example, the
multi-hydroxylated metallofullerenol Gd@C82(OH)22 was re-
cently shown to inhibit tumor metastasis through MMP
inhibition rather than through direct killing of the cancer
cells,47 thus suggesting a new, nanomedicine-based approach
in the management of tumor metastasis.48 In subsequent studies,
based on computational and experimental approaches, the
authors proposed that Gd@C82(OH)22 suppress pancreatic
cancer metastasis by inhibiting the interaction of histone
deacetylase 1 (HDAC1) and metastasis-associated protein 1
(MTA1), thus acting as a novel HDAC inhibitor.49 These
fullerene derivatives were also shown to possess intrinsic
inhibitory activity against breast cancer cells blocking epithe-
lial-to-mesenchymal transition with efficient elimination of
so-called breast cancer stem cells resulting in abrogation of
tumor initiation and metastasis.50 Taken together, these studies
thus exemplify the use of nanoparticles as drugs per se.51
Chemoresistance is the main cause of treatment failure in
advanced, metastatic cancer. Drug efflux from tumor cells by
drug transporter proteins including multi-drug resistance protein
1 (MDR1), also known as P-glycoprotein, is the most common
mechanism of chemoresistance.52 Doxorubicin is a standard
treatment for many cancers; however, its clinical use is limited
by its known dose-dependent toxicity (cardiotoxicity and
myelosuppression, i.e., decreased bone marrow activity), the
emergence of so-called multi-drug resistance – which is
explained by drug efflux by transporter proteins – and its low
specificity against cancer cells.53 Nano-based delivery systems,
with or without targeting ligands, could potentially overcome
these limitations, by reducing the side-effects and increasing the
therapeutic effectiveness of the drug.54 Interestingly, novel
approaches to circumvent chemoresistance using nanodiamonds
were recently reported. Chow et al55 showed that a complex of
nanodiamonds and doxorubicin (NDX) overcame drug efflux
and significantly increased tumor growth inhibition in mice
bearing chemoresistant tumors. The authors found that nanodia-
mond conjugation resulted in sustained drug release. To measure
drug retention in cells, the authors used cells overexpressing the
drug transporter MDR1, and found that treatment with NDX
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compared to the free drug.55 Moreover, NDX displayed less
toxicity in mice (no myelosuppression, with no mortality at the
highest doses) when compared to standard treatment with free
doxorubicin.55 In a subsequent study, nanodiamonds were used
to deliver the related chemotherapeutic drug, epirubicin to cancer
cells. Epirubicin is favored over doxorubicin for its lower
cardiotoxicity, but can also be effluxed by cancer cells via drug
transporters. Wang et al56 reported that nanodiamond-epirubicin
complexes displayed higher efficacy compared to unmodified
standard treatment in killing both normal cancer cells and cancer
stem cells in vitro and in vivo, in a model of hepatic cancer
enriched for chemoresistant cancer stem cells. The authors also
documented that the association of epirubicin to nanodiamonds
prevented efflux of the drug by drug transporters.56 Notably, this
was a function specific to nanodiamond-mediated drug delivery
as epirubicin delivery by liposomes failed to enhance drug
retention. Together, these studies suggest novel approaches for
overcoming chemoresistance using nanodiamonds. It will be of
interest to learn whether nanodiamonds are susceptible to
degradation, as shown for other carbon-based nanomaterials
(below).
A second major area in nanomedicine is imaging and
diagnostics and carbon-based nanomaterials have received
much attention also in this regard. Moreover, as already alluded
to previously, therapeutic and diagnostic modalities can be
combined in multi-functional theranostic devices.4 Here, we
will touch briefly on this topic [for a more comprehensive
discussion, refer to Chen et al4 and Yoo et al57].
CNTs have been studied intensively for multiple imaging
modalities including fluorescence imaging, photoacoustic and
Raman imaging, and so on; some examples are provided here.
De La Zerda et al58 demonstrated that SWCNTs conjugated with
cyclic Arg-Gly-Asp (RGD) peptides can be used as a contrast
agent for photoacoustic imaging of malignant glioma tumors in
mice. Intravenous administration of these targeted nanotubes to
mice bearing tumors showed eight times greater photoacoustic
signal in the tumor than mice injected with non-targeted
nanotubes. Ghosh et al59 reported on the use of SWCNTs to
visualize deep, disseminated tumors in vivo which could
facilitate surgical excision of model ovarian cancers with
submillimeter precision. Delogu et al.60 provided evidence for
the use of MWCNTs as ultrasound contrast agents, in a large
animal model (pig). The authors could demonstrate that the
ultrasound signal of functionalized MWCNTs was higher than
GO, pristine MWCNTs, and functionalized SWCNTs. Similarly,
graphene and its derivatives are also investigated as optical or
non-optical imaging agents.57 For instance, as already men-
tioned previously, novel, PEG-functionalized GO-iron oxide
nanoparticle hybrid materials were recently developed for in vivo
tri-modal fluorescence, photoacoustic, and magnetic resonance
imaging.41 In another related example, Shi et al61 reported on the
application of multi-functional sensors based on GO decorated
with both iron oxide and gold nanoparticles and functionalized
with PEG molecules. Additionally, graphene quantum dots, an
emerging fluorescent material, were shown to act as photody-
namic therapy agents, with a quantum yield that is higher than for
any other known PDT agent.62Fullerenes such as C60 have been functionalized using metals
for use as contrast agents and radiotracers. Indeed, metalloful-
lerenes have been explored as contrast agent for MRI for more
than a decade.46 Moreover, Shi et al63 recently developed a
hybrid nanoplatform with multi-functional properties for com-
bined cancer diagnosis, photodynamic therapy, radiofrequency
thermal therapy, and magnetic targeting. Hence, the authors
produced a C60-iron oxide nanoparticle composite functionalized
by PEG and decorated with folic acid, a widely used tumor
targeting molecule, and were able to achieve synergistic,
multi-modal ablation of tumors in sarcoma-bearing mice.63
More information on the biodistribution and long-term toxicity is
needed, but the approach aptly demonstrates the theranostic
potential of carbon-based nanomaterials. Nanodiamonds
presenting nitrogen-vacancy centers have intrinsic fluorescence
properties and nanodiamonds, as well as the metal hybrid
nanodiamonds, therefore present themselves as interesting tools
for imaging and diagnostics [see Mochalin et al15 for a review].
For instance, Fu et al64 reported on the use of fluorescent
nanodiamonds as single-particle biomarkers for in vitro studies.
Biosensors are important tools in biomedical research and are
becoming an essential part of modern healthcare.65 By taking
advantage of their unique electrical and optical properties, CNTs
can be integrated into highly sensitive sensors and probes.66 For
instance, Iverson et al67 showed that single-stranded DNA
oligonucleotide-functionalized SWCNTs can be used for the
selective detection of local nitric oxide (NO) concentrations
in vivo in mice following intravenous injection. NO is an
important signaling molecule involved in many physiological
and pathological processes. The authors also found that the
SWCNTs can function as implantable inflammation sensors for
NO detection, with no intrinsic immune reactivity or other
adverse responses. Due to the absence of photobleaching, the
SWCNT-based sensors are highly stable (no negligible change of
activity was noted after 400 days).67 In a recent study,
biocompatible GO biosensors for detecting blood glucose levels
over a broad concentration range were developed by covalently
attaching the amine groups of glucose oxidase to the carboxyl acid
groups of GO.68 Furthermore, Jiang et al69 reported a novel
approach for electrical sensing of NO using hemin-functionalized
graphene. The graphene-hemin sensors could respond rapidly to NO
in physiological environments with sub-nanomolar sensitivity.
Additionally, in vitro studies showed that the sensors could be
used for the detection of NO released from macrophages and
endothelial cells.69
Finally, carbon-based nanomaterials are emerging as poten-
tial candidates for the development of synthetic scaffolds in
tissue engineering [see Ku et al70 for a comprehensive review].
CNTs offer several characteristics similar to those of the
extracellular matrix, the environment in which cells physiolog-
ically migrate and proliferate to form tissues and organs. Cellot
et al71 provided theoretical and experimental evidence that CNTs
might improve neuronal performance by favoring electrical
‘shortcuts’ between the soma or cell body of neurons and the
dendrites. Bosi et al72 recently reported a biocompatible,
synthetic polymer based-scaffold that allowed the development
of 3-dimensional hippocampal cultures. Furthermore, the authors
endowed the scaffold with nano-topographies by incorporating
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cultured neuronal circuits.72 In addition, nanodiamonds have
been reported to act as a platform for neuronal growth73 while
hybrid structures of GO and silica nanoparticles promoted
growth and alignment of human neural stem cells.74 Graphene is
also envisioned for artificial retinas, i.e., prosthetic devices that
interface with the optical nerve; see the Science and Technology
roadmap of the Graphene Flagship Project.14 However, for such
applications to be realized – indeed, for any biomedical
applications of nanomaterials – a detailed understanding of the
biological interactions of the nanomaterial, including bio-corona
formation, is needed, and the propensity for degradation and/or
clearance in vivo should also be evaluated.
Bio-corona formation on carbon-based nanomaterials
In biological environments, nanomaterials are rapidly coated
with proteins, lipids and other biomolecules.75 This so-called
bio-corona formation confers a new biological ‘identity’ to the
nanomaterial, and this is of key importance for the subsequent
biological (and toxicological) interactions of nanomaterials in
living systems.8,76 Moreover, it is important to consider the
‘shifting identities’ of a nanomaterial as it translocates from one
biological compartment to another (for instance, from the lungs
or the gastrointestinal tract to the systemic circulation) and from
the extracellular environment to intracellular locations (cyto-
plasm, lysosomes, etc).77 The bio-corona could also exhibit
dynamic changes when passing through these different environ-
ments, for instance as a result of enzymatic processing of the
corona constituents.75 For targeted nanomedicines, it is
important to consider whether the acquired bio-corona could
‘mask’ the ligands and thereby prevent targeting to the desired
location, for instance, to a tumor.78 On the other hand, it also
remains possible that the bio-corona could display functional
epitopes that may engage specific cellular receptors79; indeed,
nanomaterials could undergo ‘functionalization’ in vivo and an
important challenge is thus to decipher and to control this
phenomenon.80 In the following sections, we discuss bio-corona
formation in relation to the biological behavior of nanomaterials,
and more specifically in relation to targeting of nano-carriers.
There are several experimental and theoretical studies on
bio-corona formation on CNTs, and also some recent studies on
GO. Dutta et al81 identified albumin as the major fetal bovine or
human serum/plasma protein adsorbed onto SWCNTs and noted
that the bio-corona plays an important role in modulating cellular
uptake of SWCNTs in murine RAW264.7 macrophage-like
cells, presumably through interactions with scavenger receptors.
Ge et al82 employed experimental and theoretical approaches to
study the interaction of four major serum proteins – bovine
fibrinogen (BFG), immunoglobulin, transferrin, and bovine
serum albumin (BSA) – with SWCNTs and found that serum
protein-coated SWCNTs caused less cytotoxicity than uncoated
SWCNTs in the human leukemia cell line (THP-1) and human
umbilical vein endothelial cells (HUVECs), with BFG showing
the most pronounced effect. Notably, BFG was found to
rearrange themselves on the SWCNT surface in the most
compact manner and the most layers (five layers as compared to
two or three layers for other proteins), which may potentiallyexplain why this protein was more effective at protecting cells
from the exposure of SWCNTs.82 Using an 80-member
combinatorial MWCNT library, Gao et al83 found that surface
chemistry modification reduced the immune perturbations of
MWCNTs both in vitro and in vivo. Furthermore, these authors
demonstrated that the modified MWCNTs changed their
preferred binding pattern from mannose receptor to scavenger
receptor, in the THP-1 macrophage model.83 While the role of
the bio-corona was not investigated in the latter study, it is more
than likely that the surface modifications altered the binding of
serum proteins both in vivo and in cell culture which in turn
mediated the ‘switch’ from mannose receptor to scavenger
receptor-mediated uptake. We recently noted that serum proteins
are accountable for the Toll-like receptor (TLR)-dependent
signaling of SWCNTs in primary monocyte-derived macro-
phages, while GO did not display such effects (manuscript in
preparation). Taken together, macrophage recognition of CNTs
seems to depend critically on the bio-corona and different CNT
surface properties may impart critical changes in the composition
of the bio-corona and hence affect the biological outcomes.
GO has an extremely high protein adsorption capacity. Hu et
al84 noted that the cytotoxicity of GO toward human A549 lung
carcinoma cells was greatly mitigated in presence of 10% fetal
bovine serum, the concentration usually employed in cell culture
medium. The authors noted that GO had a much higher capacity
for protein loading when compared to both SWCNTs and
MWCNTs. Similarly, Chong et al85 also found that adsorption of
serum proteins onto GO drastically reduced their cytotoxicity
toward A549 lung carcinoma cells and found that GO exhibits a
dramatic enhancement of adsorption capacity compared to
SWCNTs. In a subsequent study, coating of GO with BSA
was suggested to reduce cytotoxicity toward A549 cells by
reducing the physical interaction of GO with the cell
membrane.86 It is noted, however, that A549 is a notoriously
robust carcinoma cell line not reflective of normal cell
physiology. It will therefore be of interest to perform similar
studies using professional phagocytic cells (macrophages) or
other primary immune-competent cells. Using molecular dy-
namics (MD) simulations, aromatic residues were found to
contribute significantly to the protein adsorption due to the
strong π-π stacking interactions between their aromatic rings and
the graphene sp2-carbons.87 In addition, basic residues like
arginine played an equally or even stronger role during this
process. Furthermore, in another MD study, the dependence on
surface curvature was investigated for adsorption of BSA onto
CNTs of increasing radius versus a flat graphene sheet, and the
results confirmed that protein adsorption capacity is indeed
enhanced on flatter surfaces.88
Most studies to date on the bio-corona have been conducted
using human plasma or bovine serum as a source of
biomolecules reflective of the conditions in the blood or in cell
culture, respectively.75 However, following the introduction of
nanomaterials into other compartments, such as the lung or the
gastrointestinal tract, nanomaterials may encounter a different
environment leading to the formation of a distinct bio-corona. In
the first study on the potential in vivo formation of a bio-corona
in the lungs, Kapralov et al89 found that pharyngeal aspiration of
SWCNTs in mice resulted in adsorption of lung surfactant
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protein-lipid bio-corona facilitated uptake of SWCNTs by
murine RAW264.7 macrophage-like cells. In a related in vitro
study using amino- and carboxyl-modified MWCNTs, Gasser
et al90 found that surfactant lipids (derived from Curosurf) bind
unspecifically to the different functionalized MWCNTs, in
contrast to plasma proteins which showed characteristic binding
patterns. They also noted that the pattern of plasma protein
binding was altered when MWCNTs had been previously coated
with pulmonary surfactant. This could be interpreted to suggest
that nanomaterials retain a ‘memory’ of previous biological
environments or compartments in vivo, for instance, upon
translocation across the lung–blood barrier.
As we have discussed, the adsorption of proteins and other
biomolecules onto the surface of nanomaterials can influence the
‘identity’ and biological behavior of the nanomaterials. Con-
versely, the interactions between biomolecules and nanomater-
ials can also lead to altered conformational and orientational
changes of the biomolecules, potentially revealing cryptic
epitopes that could trigger immune responses via specific cell
surface receptors.79 Indeed, one may view the altered proteins on
the surface of nanomaterials as ‘nanomaterial-associated molec-
ular patterns’ or NAMPs analogous to the pathogen-associated
molecular patterns (PAMPs) displayed by microbes.9 Moreover,
protein adsorption by nanomaterials, not least by GO, which
presents a vast surface for protein binding, can lead to inhibition
of enzyme activity. Hence, recent studies have shown that
carbon-based nanomaterials can inhibit the bacterial enzyme,
VIM-2 belonging to the clinically relevant class of metallo-
β-lactamases that provide resistance to a broad spectrum of
antibiotics including penicillin; the inhibition was noncompet-
itive and was attributed to hydrophobic interactions with the
enzyme.91 Moreover, adsorption of VIM-2 was further probed
using protein displacement assays and it could not displace or be
displaced by BSA. We recently found that both SWCNTs and
GO inhibit CYP3A4, a major drug-metabolizing enzyme and
that this was mitigated when the nanomaterials were pre-coated
with BSA (submitted for publication). In addition, previous
studies have shown that GO is an inhibitor of α-chymotrypsin92
and β-galactosidase93 while, on the other hand, PEGylated GO
can apparently boost the activity of trypsin, but has no effect on
chymotrypsin or proteinase K, which are also serine proteases.94
Shurin et al33 reported that GO can trigger alveolar macrophage
production of chitinases, enzymes whose expression is associ-
ated with asthma, in mice and theoretical and experimental data
suggested that GO could directly interact with and inhibit
chitinase activity. Whether inhibition of chitinases also occurs in
a complex biological environment, in the presence of lung
surfactant or other biomolecules, remains to be understood.
The complement system is a part of the innate immune system
that helps or complements other humoral (antibodies) or cellular
(phagocytes) components of the immune system to clear
pathogens. Importantly, carbon-based nanomaterials, not least
CNTs, have been shown to bind complement factors and this
phenomenon thus represents a special case of bio-corona
formation which is of considerable relevance as complement-
mediated toxicity is a major limiting factor for nanomedicine
applications following intravenous administration of the nano-carrier [reviewed in Moghimi95]. There are three established
pathways of complement activation: the so-called classical,
lectin and alternative pathways. The majority of complement
activation studies with nanomaterials – including CNTs and GO
with or without polyethylene glycol (PEG) modification on the
surface – have focused mostly on the classical and alternative
pathways.96-98 However, as recently pointed out by Moghimi
et al,99 there is now evidence to suggest that many nanoparticles
may trigger complement activation through the lectin pathway,
which involves carbohydrate recognition, even though these
nanoparticles do not per se express surface-exposed sugars.
Instead, according to Moghimi et al99, and see references
therein], functionalized nanoparticles may ‘mimic’ pathogens by
virtue of the projected polymeric surface architecture that
resembles structural motifs of peptidoglycan constituents of
pathogens which then triggers the lectin pathway.
Nanomaterials intended for use as drug delivery vehicles are
commonly functionalized using long hydrophilic polymers such
as poly(acrylic acid), chitosan or PEG, as this increases the
biocompatibility of these systems and is thought to reduce
non-specific protein adsorption and clearance by phagocytic
cells of the reticuloendothelial system (RES), thereby promoting
passive targeting to the desired location, such as a tumor.100
However, as we shall discuss in more detail below, PEG
functionalization does not completely prevent protein adsorp-
tion. Moreover, to effectively counter the non-specific uptake by
phagocytic cells, PEG molecules typically need to have a
molecular weight in excess of 2 kDa, which adds considerably to
the overall hydrodynamic diameter of the nanoparticles. In recent
years, zwitterionic coatings have been explored as an alternative
strategy to endow nanoparticles with “stealth” properties [see
Pombo García et al101 for an excellent review]. Because such
coatings can be constructed from low-molecular weight
materials they provide an opportunity to develop ultra-small,
excretable nanoparticles for biomedical applications.101 Choi
et al102 demonstrated renal filtration and urinary excretion of
inorganic, metal-containing nanoparticles with zwitterionic or
neutral organic coatings. Notably, zwitterionic coating using the
amino acid cysteine prevented protein adsorption while yielding
the highest solubility and the smallest hydrodynamic diameter.
In comparison, although neutral, PEGylated nanoparticles did
not bind serum protein, it was not possible to synthesize such
particles with a hydrodynamic diameter b10 nm; shorter PEG
chains resulted in insoluble particles.102
Active targeting of nanoparticles is also frequently deployed.
For instance, folic acid (FA) or transferrin, recognized by the
folate receptor and transferrin receptor, respectively, are
commonly used in an attempt to increase cellular uptake of
drug-loaded carriers in cancer cells overexpressing these
receptors.103 However, if it is true that all nanoparticles are
rapidly coated with biomolecules in a living organism, then it is
also possible that the additional layer(s) of proteins (and other
biomolecules) could obscure the targeting ligands that have been
grafted onto the surface of the nanoparticles. Indeed, in a recent
in vitro study using transferrin-conjugated nanoparticles, Salvati
et al78 found that proteins in the cell culture medium can shield
transferrin from binding to its cognate receptors on cells. Thus,
although nanoparticles continued to enter the cells, the targeting
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observed that specific, i.e., FA-dependent uptake of FA-conjugated
iron oxide nanoparticles by human ovarian cancer cells expressing
the corresponding receptor was observed only in the presence of
serum proteins, possibly due to a stabilizing effect of the serum
proteins on the functionalized nanoparticles in vitro.104 However,
while Fe3O4-SiO2-FA particles were specifically internalized,
Fe3O4-PEG-FA nanoparticles did not undergo specific (targeted)
uptake in the samemodel cell line; it is conceivable that the targeting
ligand (FA) on the PEGylated particles was embedded in amatrix of
polymers and therefore not accessible for binding to its receptor.104
Indeed, Dai et al105 reported that backfilling the surface of a targeted
nanoparticle with PEG molecules reduces protein corona formation
and noted that the length of the PEGmolecules must be less than the
length of the ligand linker; otherwise, PEG interferes with the
binding of the targeting ligand to its cellular receptor. More recently,
it was demonstrated that the formation of a protein corona does
not significantly influence the targeting ability of antibody-
functionalized polymeric particles toward human colon cancer
cells.106 In another recent study. Hadjidemetriou et al107
reported on the formation of a bio-corona on clinically relevant,
antibody-functionalized nanoparticles (liposomes) in mice. The
authors found that both in vitro and in vivo formed protein
coronas significantly reduced cellular internalization of the
antibody-conjugated liposomes, using human cervix or breast
cancer cell lines (however, in vivo targeting was not evaluated);
notably, the in vivo corona formation did not completely prevent
the targeting capability.107 Thus, it appears that the bio-coronamay
impact on targetability of nanomedicines, but it is unlikely to be the
sole critical factor determining their behavior.
Turning now to targeting of carbon-based nanomaterials, we
previously reported on in vivo targeting of intratumoral
regulatory T cells (Treg) using PEG-modified SWCNTs.108
We focused our attention on the glucocorticoid-induced
TNFR-related receptor (GITR), as it showed higher expression
on intratumoral versus peripheral (i.e., splenic) Treg compared to
other reported Treg-specific markers. Our in vivo investigations
showed that PEG-SWCNTs armed with GITR ligands targeted
Treg residing in a melanoma xenograft more efficiently then
intratumoral non-Treg or splenic Treg.108 The latter result was
likely accomplished through a combination of passive tumor
targeting (i.e., enhanced permeability and retention effect, EPR)
due to enhanced tumor vascular permeability and active targeting
of markers enriched in intratumoral Treg. This example of
intratumoral immune cell targeting thus points toward novel,
nano-based immunotherapies against cancer. Further examples
of targeted SWCNTs are discussed in the following section.
Hong et al109 demonstrated that GO can be specifically directed
to the tumor neovasculature in vivo through targeting of CD105,
a vascular marker for tumor angiogenesis (Figure 2). Notably,
incorporation of an active targeting ligand (TRC105, a
monoclonal antibody that binds to CD105) led to significantly
improved tumor uptake of functionalized GO, which was
specific for the neovasculature.109 The administration of a
blocking dose of TRC105 before injection of the nano-graphene
significantly reduced the tumor uptake which demonstrated
CD105 specificity. Hence, although one might assume that the
masking of targeting ligands would be of particular concern forgraphene-based materials, as the potential for protein adsorption
is considerable, this study suggests that relevant targeting can in
fact be achieved in vivo.
Finally, it is pertinent to note that the molecular composition
of biological fluids in patients suffering from cancer or other
diseases is unlikely to resemble the normal situation. Indeed,
recent studies on cellular uptake of GO have suggested that
attention should be focused on the ‘personalized bio-corona’
resulting from differences in protein content in human plasma
from various types of disease.110 This is a potentially important
challenge for the nanomedicine community.
Biodistribution of carbon-based nanomaterials
Understanding the fate and behavior of carbon-based
nanomaterials in vivo is imperative for the clinical translation
of these materials. Pharmacokinetic (PK) profiling addresses the
adsorption, distribution, metabolism, and excretion (ADME) of a
drug or nanomaterial in vivo [see Moghimi et al111 for a review].
Metabolism (or, degradation) of carbon-based nanomaterials is
discussed in a subsequent section. Here, we focus on other
aspects of in vivo biodistribution of nanomaterials.
Drug molecules diffuse and distribute freely throughout the
body, causing unpredictable or undesirable effects in bystander
tissues while also limiting the achievement of doses needed for a
therapeutic response. One of the great promises of nanomedicine
is the local or targeted delivery of drugs. Efficient targeting
would allow for a reduced systemic dosage meaning also a
reduced toxicity while resulting in relatively higher or more
efficient dosage at the desired target site.112 In an excellent and
very recent review, Ferrari and co-workers highlighted the
biological barriers that drug-loaded nanoparticles encounter
upon intravenous administration.113 These barriers include, for
instance, opsonization and subsequent sequestration by the RES,
as discussed at length in the present review, as well as
hemorheological/blood vessel flow limitations, and they prevent
efficacious, site-specific delivery to tumors, as well as in other
clinical conditions. Tasciotti et al114 developed a multi-stage
delivery system designed specifically to circumvent several
biological barriers after intravascular delivery. In this paradigm,
stage-1 mesoporous particles were loaded with stage-2 nanopar-
ticles, i.e., quantum dots (QDs) or SWCNTs, which in turn could
carry active agents or higher-stage particles. The authors
reasoned that by loading the stage-2 nanoparticles inside the
pores of the stage-1 particles, RES uptake would be prevented. In
this manner, the mesoporous particles would transport and
protect a payload of nanoparticles and bioactive agents
throughout their journey in the circulatory system.114 To escape
circulation, as in the case of drug delivery to a solid tumor, the
size of the nanoparticles is obviously critical, but it is also
important to note that the EPR phenomenon may vary
dramatically with regard to the degree of tumor vascularity.115
Moreover, while the presence of a targeting ligand (see previous
section for a discussion on active targeting) does not seem to
significantly affect extravasation of nanoparticles, inefficient
extravasation could significantly affect targeted delivery.112 This
means that both passive and active targeting mechanisms are
likely to play a role.
Figure 2. Targeting of tumor vasculature with graphene oxide. In vivo PET/CT imaging of 64Cu-labeled GO conjugates in breast tumor-bearing mice. Left panel
shows serial coronal PET images of tumor-bearing mice at different time points post-injection of 64Cu-NOTA-GO-TRC105, 64Cu-NOTA-GO, or
64Cu-NOTA-GO-TRC105 after a pre-injected blocking dose of TRC105. Tumors are indicated by arrowheads. Right panel displays representative PET/CT
images of 64Cu-NOTA-GO-TRC105 in tumor-bearing mice. Reprinted from: Hong H, Yang K, Zhang Y, Engle JW, Feng L, Yang Y, Nayak TR, Goel S, Bean
J, Theuer CP, Barnhart TE, Liu Z, Cai W. In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano.
2012;6(3):2361-70, with permission from American Chemical Society.
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nanomaterials, appropriately labeled nanomaterials are needed,
or one may capitalize on their intrinsic physicochemical
properties.116 In an early effort to monitor the fate of CNTs,
Singh et al117 examined the PK behavior of water-soluble,
SWCNTs functionalized with the chelating molecule DTPA and
labeled with 111In for imaging purposes. The authors noted that
the CNTs were not retained in the liver or spleen upon
intravenous administration in mice, and that the functionalized
CNTs were rapidly cleared from systemic blood circulation
through the renal excretion route with a blood circulation
half-life of 3.5 h. This ‘paradoxical’ glomerular filtration of
SWCNTs was also reported by others.118 Subsequent studies on
the retention of functionalized MWCNTs in the organs of mice
showed that the degree of chemical functionalization determines
tissue distribution and excretion profile; hence, increasing the
degree of functionalization enhanced renal clearance, while
lower functionalization promoted RES accumulation (i.e., liver
and spleen).119 Additionally, using similarly radiolabeled
MWCNTs, the authors could show that the diameter of the
functionalized MWCNTs also affects their organ distribution
in vivo in mice.120 Using, 125I-labeled nanographene sheets (i.e.,
GO) functionalized with PEG, Yang et al121 demonstrated that
the nanomaterial mainly accumulated in the liver and spleen after
intravenous administration; substantial bone uptake was also
noted at early time points, possibly owing to macrophage uptake
in the bone marrow. However, the PEGylated GO was gradually
cleared (and/or degraded), without appreciable toxicity up to
3 months post-exposure.121 In a very recent study, Jasim et al122
studied the tissue distribution of radiolabeled and chemically
functionalized GO and found that the injected material
accumulated predominantly in the liver and spleen while
evidence for renal excretion was also provided. As discussed
by the authors, the biological fate of graphene-based materials islikely to depend both on lateral dimension and thickness (i.e.,
layer number) as well as on the degree of functionalization,
which may play an important role for subsequent biological
interactions in vivo including bio-corona formation.123
Cherukuri et al124 investigated the distribution of chemically
pristine, non-labeled SWCNTs upon intravenous administration.
The authors made use of the intrinsic near-infrared fluorescence,
a property of individualized or debundled SWCNTs, to measure
the blood elimination kinetics and to identify the target organs in
rabbits exposed to the nanomaterials. First, as CNTs are
hydrophobic and tend to form aggregates, the SWCNTs were
ultrasonically dispersed in artificial surfactant, Pluronic F108.
The results showed that the SWCNT concentration in the blood
decreased exponentially with a half-life of 1 h.124 Twenty-four
hours after administration, significant concentrations of
SWCNTs were found only in the liver. Notably, in separate
in vitro experiments, the authors determined that the surfactant
was displaced within seconds by serum proteins suggesting that
the PK results obtained are reflective of the fate of SWCNTs with
a bio-corona of endogenous (serum) proteins rather than a
synthetic surfactant.124 Nonetheless, the retention of the near-IR
fluorescence implied that the SWCNTs remained disaggregated
in vivo. In another study using pristine, 13C-labeled SWCNTs,
major accumulations were seen in liver, spleen, and lung
following intravenous injection.125 Thus, it is clear that the
biodistribution of pristine versus functionalized CNTs differs
greatly, with the former being predominantly trapped in the RES
organs, while the latter favor a renal excretion route.116
In a recent study, a novel approach was developed to monitor
the distribution of carbon-based nanomaterials at the organ and
sub-organ level. Chen et al126 thus reported on label-free mass
spectrometry imaging to detect MWCNTs, single-layer GO, and
carbon nanodots (CDs) in mice based on their intrinsic carbon
cluster fingerprint signal. With this approach, it was observed
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kidneys, whereas all three nanomaterials were detected in the red
pulp of the spleen, following intravenous administration.
Evidence for clearance of the CNTs and CDs via the renal
excretion route was also provided, in line with previous
studies.117,127 The highest concentration of MWCNTs was
found in the marginal zone of the spleen (the interface between
the non-lymphoid red pulp and the lymphoid white pulp), where
particulate antigens from the circulation are trapped and
presented to the lymphocytes in the spleen126 (Figure 3). This
level of detail is difficult to achieve by other means. Overall, this
new mass spectrometry method has the potential to be used as a
general approach for the detection of carbon-based nanomater-
ials in tissue samples. As pointed out,128 the method does not
indicate whether the nanomaterials have been transformed
in vivo. Nevertheless, other methods, such as Raman confocal
imaging, could provide such information.129
In nanomedicine, it is common to modify the surface of the
nanomaterial with polymers such as PEG in order to avoid rapid
clearance by the immune system. This has been shown to
increase the circulation half-life of the nanomaterial. Liu et al130
reported on the biodistribution of radiolabeled SWCNTs in mice
and determined the effect of PEG chain length on the
biodistribution and circulation of the SWCNTs. They noted
that effectively PEGylated SWCNTs exhibited relatively long
blood circulation times and low uptake by RES organs.
Moreover, efficient targeting of tumors in mice was achieved
with SWCNTs coated with PEG chains linked to an arginine-
glycine-aspartic acid (RGD) peptide.130 Notably, injection of aFigure 3. Sub-organ biodistribution of carbon nanotubes. Laser desorption/ion
technique that can map chemical compounds in biological samples. From left to ri
of MWCNTs; heat map showing the ion intensity distribution (m/z 72.0) of MW
MWCNTs in the red pulp (red arrow), white pulp (white arrow) and marginal zon
mass spectra of red and white pulp regions are depicted to the far right. Reprinted
Mass spectrometry imaging reveals the sub-organ distribution of carbon nanom
Publishing Group.blocking dose of RGD into mice bearing αvβ3-positive tumors
significantly reduced the uptake of SWCNT-PEG-RGD in the
tumor. However, while PEGylation has been shown to reduce
protein adsorption, this surface modification does not entirely
prevent bio-corona formation. The question, therefore, is
whether and to what extent the bio-corona influences the
biodistribution of PEGylated nanomaterials. In a recent study,
we investigated the protein corona adsorbed onto SWCNTs
modified with 2 kDa PEG chains by using large-scale gel-based
proteomics.131 We identified more than 500 proteins in the
bio-corona; a subset of these plasma proteins were selected and
grouped according to their physiological function. Coagulation
proteins, immunoglobulins, apolipoproteins, and complement
factors were among the proteins bound by the PEGylated
SWCNTs.131 Interestingly, PEG conformation had a stronger
influence on the protein corona repertoire than nanotube surface
charge. Moreover, the bio-corona affected the biodistribution of
the SWCNTs in mice. Hence, a change in PEG conformation
from mushroom to mushroom-brush transition affected the
competitive adsorption of the major constituents of the protein
corona and promoted shorter blood circulation time, faster renal
excretion, and higher relative spleen versus liver uptake of
PEG-SWCNTs.131 Our data thus suggest that the bio-corona,
along with steric stabilization, may mediate the action of PEG
conformation on the PK profile of PEG-modified SWCNTs.
As discussed above, the PEG chains have to be of high
molecular weight (N2 kDa) in order to avoid RES clearance.101
Zwitterions on the other hand provide a highly stable coating on the
surface of nanomaterials with little change in the hydrodynamicization (LDI) mass spectrometry imaging (MSI) is an emerging label-free
ght: Optical image of a spleen tissue slice from mice following administration
CNTs in a spleen tissue slice; magnified view showing the distribution of
e (purple arrow) of the spleen. Scale bars, 2 mm. Finally, representative LDI
from: Chen S, Xiong C, Liu H, Wan Q, Hou J, He Q, Badu-Tawiah A, Nie Z.
aterials. Nat Nanotechnol. 2015;10(2):176-82, with permission from Nature
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adsorption and promote cellular uptake by tumor cells, Yuan
et al132 synthesized surface charge switchable nanoparticles based
on zwitterionic polymers for drug delivery. The authors noted that,
in physiological conditions the nanoparticles showed prolonged
circulation time as a result of the reduced protein absorption
afforded by the zwitterionic polymer. After accumulating in the
relatively acidic tumor tissue, the zwitterionic polymer-based
nanoparticle switched its surface to a positive charge, which
facilitated tumor cell uptake and delivery of the anti-cancer drug,
doxorubicin. Thus, zwitterionic coatings present an alternative to
PEG and offer opportunities for the design of “smart” nanoparticles
for biomedical applications.101
Finally, in an intriguing twist on tumor targeting, Smith
et al133 recently reported that specific immune cell populations in
the blood may act as Trojan horses to deliver CNTs to tumors. In
general, as pointed out by the authors, tumor targeting of
nanoparticles may transpire both via passive and active
mechanisms, including extravasation from the blood stream
into the tumor (i.e., the EPR effect) and ligand-mediated
targeting to tumor cells or to the tumor vasculature, examples
of which were provided in previous sections of the present
review. Smith et al133 hypothesized that circulating cells in the
blood take up nanoparticles and deposit them in the tumor, thus
serving to complement the other mechanisms. Indeed, using
severe combined immunodeficient (SCID) mice lacking func-
tional B and T cells, the authors discovered that PEG-modified
SWCNTs are selectively taken up by a single subset of
circulating immune cells, the Ly-6Chi monocytes.133 The
mechanism for this cellular uptake was not disclosed, but it is
noted that several known opsonins (i.e., phagocytosis-promoting
factors) are found in the bio-corona formed on PEGylated
SWCNTs.131 Notably, these monocytes are known to differen-
tiate into so-called tumor-associated macrophages (TAMs) and
are attracted to hypoxic regions of the tumor, which may be of
particular relevance in cancer treatment.134 The authors found
that the uptake of SWCNTs in circulating monocytes promoted
the delivery to tumors and, remarkably, that the conjugation of a
targeting ligand (RGD) to the CNTs promoted the homing of
SWCNT-loaded monocytes to tumors when compared to
non-conjugated and control peptide-conjugated SWCNTs.133
These results suggest a novel mechanism for tumor targeting and
demonstrate that PEGylation does not necessarily prevent
immune cell recognition. Several questions arise: What is the
mechanism of the selective (receptor-mediated) uptake of the
SWCNTs? How does RGD functionalization of SWCNTs
promote homing of these cells to tumors? Furthermore,
following infiltration of this subset of monocytes into the
tumor, are the SWCNTs (and their cargo) released? Finally, do
the PEG-SWCNTs undergo biodegradation in TAMs?
Biodegradation of carbon-based nanomaterials
As discussed in preceding sections, there has been a
widespread concern that certain CNTs, in particular, may exhibit
asbestos-like pathogenicity, in part due to the fiber-like
morphology, but also based on the assumption that CNTs are
biopersistent, like asbestos fibers. However, several groups havereported in recent years that carbon-based nanomaterials are
susceptible to biodegradation.135 Importantly, these studies have
highlighted a key role for the innate immune system in the
enzymatic ‘digestion’ of carbon-based nanomaterials.136 These
observations suggest that the potentially detrimental effects of
such materials may be mitigated thereby allowing the materials
to be more widely applied in nanomedicine. The fact that our
immune system is capable of ‘sensing’ and destroying
carbon-based nanomaterials through oxidative reactions may
not come as a surprise given that such nanomaterials have been
shown to occur abundantly in nature.137,138 Moreover, diamond,
graphitic, fullerenic and amorphous carbon particles can form in
the flame of a candle.139 Thus, this suggests that mankind has
been exposed to carbon-based nanomaterials since the dawn of
time and it is conceivable that defense mechanisms have evolved
to protect us not only from microbes but also from other foreign
particles.
While chemical degradation of carbon-based nanomaterials
was demonstrated through either harsh chemical treatment with
concentrated mineral acids140 or destruction of graphitic lattices
through high temperature treatment,141 neither of these processes
are relevant once these nanomaterials find their way into a living
organism. However, peroxidases which have strong redox
potentials, are known to catalyze oxidation of foreign particles
and pathogens with hydrogen peroxide in biological systems.
Allen et al142 initially demonstrated the degradation of SWCNTs
using a plant-derived enzyme, horseradish peroxidase (HRP).
HRP contains a single protoporphyrin IX heme group which in
its inactive form exists in its ferric (Fe3+) oxidation state and
upon reaction with hydrogen peroxide forms a ferryl oxo iron
(Fe4+ = O) known as Compound I.143 The high redox potential
of Compound I enables degradation of carboxylated SWCNTs
due to the close proximity of SWCNTs to the heme catalytic
active site.135 We and others have documented the degradation
of single- and multi-walled CNTs and GO by HRP and
H2O2.
142,144-147 Moreover, lignin peroxidase produced by
white rot fungus also has the capacity to induce oxidative
biodegradation of fullerenes, SWCNTs, and graphene
nanoribbons148-150 while recent studies have demonstrated
biodegradation of MWCNTs and GO by various bacteria.151,152
The catalytic heme active site is also characteristic of
mammalian peroxidases including neutrophil myeloperoxidase
(MPO), eosinophil peroxidase (EPO), and lactoperoxidase
(LPO), suggesting avenues for biological degradation of
carbon-based nanomaterials. Indeed, MPO, EPO, and LPO
have all been shown to catalyze the degradation of carboxylated
SWCNTs in vitro in the presence of H2O2 and halide ions
through the production of reactive radical intermediates in
addition to hypohalous acids153-155 (Figure 4). Degradation of
oxidized SWCNTs has been demonstrated upon incubation with
MPO and H2O2, in addition to incubation only with sodium
hypochlorite (NaOCl). However, only the combined effects of
MPO, H2O2, and NaCl (resulting in the production of
hypochlorous acid, HOCl) allowed for rapid degradation of
oxidized SWCNTs.153 In addition to electron microscopy-based
evidence (SEM and TEM), degradation has further been proven
by tracking decreases in the intrinsic Raman peaks of SWCNTs,
specifically the D-band (disorder in sp2 hybridized carbon
Figure 4. Enzymatic degradation of carbon nanotubes. Molecular modeling demonstrating possible SWCNT interaction sites on eosinophil peroxidase, EPO.
Upper left: The two predicted interaction sites, site 1 and site 2 of oxidized SWCNTs modified at the edge. Upper right: Overlay of the possible interaction site 1
of SWCNTs oxidized at the edge (colored in gray) and in the middle (colored in cyan). Lower left and right: The residues that are in close proximity (within 4 Å),
stabilizing the binding sites (left) site 1 and (right) site 2. Positively charged residues (arginines) that are predicted to stabilize the oxidized groups on SWCNTs
are colored in yellow. Reprinted from: Andón FT, Kapralov AA, Yanamala N, Feng W, Baygan A, Chambers BJ, Hultenby K, Ye F, Toprak MS, Brandner BD,
Fornara A, Klein-Seetharaman J, Kotchey GP, Star A, Shvedova AA, Fadeel B, Kagan VE. Biodegradation of single-walled carbon nanotubes by eosinophil
peroxidase. Small. 2013;9(16):2721-9, 2720, with permission from John Wiley and Sons.
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~1600 cm−1) with complete degradation occurring at 24 h of
incubation with MPO, H2O2, and NaCl.
153 The peroxidase-
catalyzed degradation of SWCNTs has been shown to proceed
efficiently with oxidized SWCNTs where incorporated func-
tionalities create defect sites for docking of the respective
enzymes.143 The higher the degree of the incorporated defects
the higher the rate of degradation, with pristine SWCNTs
remaining unaffected by the degradation cycle.143 The degrada-
tion of SWCNTs results in shortening of nanotube length,
leading to the production of oxidized polyaromatic hydrocarbons
and, ultimately, CO2.
143 However, detailed determination of
degradation intermediates has proven difficult as the system
contains multiple complex molecular ions and fragments
according to mass spectrometry (MS). In order to better
understand the degradation products an enzyme-free system of
GO degradation by the photo-Fenton reaction was investigated
in which the products were identified via multiple analytical
techniques (FTIR, MS, and NMR).156 The degradation was
found to proceed through an oxidation and decarboxylationmechanism ultimately resulting in oxidized hydrocarbons,
specifically aromatic rings functionalized with carboxylic acid
groups.156 These findings suggest that partially degraded GO or
CNTs could trigger genotoxicity, as shown for extracts from
HRP-degraded SWCNTs.157 Further studies using mammalian
peroxidases, in relevant in vitro and in vivo settings, are needed
to address whether partial biodegradation of carbon-based
nanomaterials elicits more or less genotoxicity when compared
to the undigested, as-delivered nanomaterials. Complete degra-
dation, however, is not expected to do so.
In addition to test-tube experiments of SWCNT degradation
using recombinant peroxidases, we and others have shown that
primary cells of the innate immune system are capable of
enzymatic degradation of SWCNTs.153,154,158 Notably, this
degradation may take place both intracellularly and extracellu-
larly. Kagan et al153 demonstrated that opsonization of SWCNTs
with immunoglobulin (IgG) promotes neutrophil uptake ex vivo
with subsequent degradation of the nanotubes. Moreover,
evidence for MPO-dependent degradation of oxidized SWCNTs
in vivo in the lungs of mice was also obtained.159 Importantly,
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granule contents including MPO and EPO, respectively, which
enables extracellular destruction of microbes, and we cannot
discount this pathway in the enzymatic degradation observed for
SWCNTs.153,154 Moreover, neutrophils can produce so-called
neutrophil extracellular traps (NETs) consisting of nuclear
chromatin fibers studded with granule proteins, and our studies
have shown that purified NETs can ‘capture’ and digest
SWCNTs, testifying to the versatility of these cells.6 In addition
to neutrophils and eosinophils, recent data also suggest that
macrophages can ‘digest’ SWCNTs.160 Neutrophils are short-
lived with a life-span of days. In contrast, tissue-resident
macrophages may persist for weeks in the context of chronic
inflammation. However, in contrast to neutrophils, macrophages
do not express significant amounts of MPO. Instead, the
oxidative metabolism and destruction of foreign bodies includ-
ing pathogens is driven by NADPH oxidase (producing
superoxide) and the inducible isoform of nitric oxide synthase
(iNOS) (producing nitric oxide), which conspire to produce a
highly potent oxidant, peroxynitrite (ONOO−).160 Using a
model of activated human THP-1 cells, Kagan et al160 recently
demonstrated peroxynitrite-driven degradation of SWCNTs.
Evidence for NADPH oxidase-dependent degradation of
SWCNTs in vivo was also provided.160 Moreover, Zhang
et al161 reported that carbon nanohorns also undergo partial
degradation in macrophage-like cell lines (RAW264.7 and
THP-1) and degradation of MWCNTs has also been reported
recently using differentiated THP-1 cells as a model.162
Importantly, in the studies cited above, degradation was shown
to occur in a complex biological environment, i.e., in cell culture
in the presence of fetal bovine serum, or in the lungs of mice,
suggesting that bio-corona formation does not prevent degrada-
tion of carbon-based nanomaterials. To probe this in further
detail, we recently investigated whether LPO-mediated degra-
dation could occur in the presence of lung surfactant.155 LPO is a
secreted enzyme that has been shown to be important for airway
defense against infection. Indeed, efficient LPO-mediated
degradation of carboxylated SWCNTs pre-coated with porcine
lung surfactant (Curosurf) was documented by Raman spectros-
copy, and we also observed biodegradation of SWCNTs in
cell-free bronchoalveolar lavage fluid.155 Thus, the presence of a
protein-lipid corona89 does not appear to interfere with
degradation. One may postulate that several complementary
pathways act together to ensure that foreign intruders – such as
nanoparticles – are recognized and cleared from the lungs,
including secreted enzymes as well as cell-based systems.
Perhaps, as previously suggested, neutrophils are initially
engaged while macrophages are called into action at a later
stage.160 Moreover, similar, macrophage-driven reactions may
take place in other compartments; for instance, recent studies
have suggested that MWCNTs stereotactically injected into the
mouse brain cortex are internalized by microglia, the resident
macrophages of the brain, and degraded.163
As mentioned before, PEGylation is commonly applied in
nanomedicine in order to reduce non-specific protein adsorption
and extend the half-life of nanomaterials in systemic circulation.
However, it is important to ask whether such modifications make
the nanomaterials impervious to enzymatic degradation. In arecent study, we noted that the presence of PEG chains on the
surface of SWCNTs may interfere with the degradation under
in vitro conditions using recombinant MPO in a PEG chain
molecular weight dependent manner, suggesting that there could
be some steric hindrance.164 However, when SWCNTs were
incubated with activated human neutrophils undergoing degran-
ulation, effective degradation of SWCNTS was observed
irrespective of whether they were PEG-modified or not, and
we provided evidence for a cooperative action of NE, a
neutrophil protease, and MPO, suggesting that neutrophils release
enzymes that can ‘strip’ the PEG chains of PEGylated SWCNTs
allowing for efficient peroxidase-driven degradation.164 Further-
more, other investigators have documented defunctionalization of
PEGylated SWCNTs in vivo following intravenous administration
in mice.165 Combined, these results imply that PEGylated CNTs
may undergo defunctionalization and degradation.
We previously developed so-called nitrogen-doped carbon
nanotube cups.166 In a recent study, we found that these hollow,
cup-shaped nano-containers can be effectively ‘corked’ with
gold nanoparticles and we have shown that MPO can ‘open’ the
corked carbon nanotube cups through detachment of the gold
nanoparticles, with subsequent enzymatic degradation of the
graphitic shells.167 Furthermore, the gold-corked carbon nano-
tube cups were demonstrated to function as drug delivery
carriers, capable of delivery of the chemotherapeutic agent,
paclitaxel to myeloid-derived suppressor cells (MDSC), with
MPO-regulated release of the drug, resulting in the differenti-
ation of MDSC into dendritic cells (DC), a property of MDSC
that has been reported to be lost in cancer.167 The findings
indicate the potential of the gold-corked carbon nanotube cups in
drug delivery applications. MDSC are known to overexpress
both MPO and inducible nitric oxide synthase (iNOS),
potentially providing a route for enzymatic degradation similar
to the peroxidase-catalyzed and peroxynitrite-mediated degra-
dation route of neutrophils and macrophages, respectively.160
Notably, not only the nano-carrier, but also the payload (drug)
may undergo degradation. In a recent study, we were able to
demonstrate that SWCNTs externally functionalized with
doxorubicin could be employed for drug delivery, and found
that the nano-carriers improved the efficacy of the drug in an
in vitro melanoma cell model due to the protection provided
against oxidative degradation exerted byMDSC present in the cell
culture.168 Thus, on the basis of these studies, one may conclude
that it is crucial to understand and control the degradation of
carbon-based nanomaterials, not only from the perspective of their
perceived toxicity, but also for the implementation of carbon-based
drug delivery vehicles. Indeed, it is important to strike the right
balance between degradation and resistance of the carrier and its
payload against oxidants generated by inflammatory cells in the
tumor microenvironment.168
GO was also found to be degraded through the same
peroxidase cycle as CNTs; however, the degradation occurs
through a slightly different mechanism. Due to preferential
binding of peroxidase enzymes such as HRP to the basal plane of
GO, as opposed to the edges of GO flakes, the graphitic lattice is
degraded from select points throughout the GO sheets resulting
in the formation of holes169 (Figure 5). Moreover, analogous to
pristine, un-oxidized SWCNTs which are resistant to enzymatic
Figure 5. Enzymatic degradation of graphene oxide. Upper panels show atomic force microscopy (AFM) images with section analysis of GO and horseradish
peroxidase (HRP) at day 0 (left) and at day 10 (right). GO with HRP has a sheet height of 5.37 nm and 9.81 nm. Holey GO has a sheet height of 1.10 nm, and the
holes were authentic at a height of 0.01 nm. Lower panels display binding poses of HRP on (from left to right) GO, holey GO, and a small sheet of GO calculated
using molecular docking studies. Reprinted from: Kotchey GP, Allen BL, Vedala H, Yanamala N, Kapralov AA, Tyurina YY, Klein-Seetharaman J, Kagan VE,
Star A. The enzymatic oxidation of graphene oxide. ACS Nano. 2011;5(3):2098-108, with permission from American Chemical Society.
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alities resisted degradation and remained intact with no evidence
of hole formation after 20 days of incubation with HRP and
H2O2.
147 More recent studies have shown that the level of
oxidation of GO directly correlates with the efficiency of
MPO-mediated degradation in vitro.169 The oxygen functional
groups provide better dispersibility of GO in aqueous media thus
facilitating the degradation of GO169; additionally, it can be
argued that the incorporated oxygen functionalities may allow
for close proximity with the active site of MPO. Furthermore, we
recently obtained evidence for degradation of GO by activated
neutrophils (manuscript in preparation). Degradation of carbox-
ylated graphene has been reported in vivo in mice following
intravenous injection. Using Raman confocal imaging, Girish et
al129 reported degradation of graphene from day 8 onwards,
beginning from the edges and growing inwards. Spleen samples
showed the most enhanced disorder leading to an almost
complete amorphization of graphene over a period of 3 months.
The authors provided evidence of phagocytosis of graphene by
alveolar macrophages, Kupffer cells and spleen bound macro-
phages, implying that the degradation of graphene was mainly
orchestrated by macrophages in the respective organs.129 In
addition, in vitro studies using murine RAW264.7 macrophage-
like cells showed development of structural disorder in the
engulfed graphene when monitored up to 7 days, supporting the
role of macrophages in their biodegradation.129 Together, the
available data suggest that both neutrophil and macrophage
mediated degradation of graphene and its derivatives is possible,
as shown for CNTs.Finally, Li et al170 reported that both PEG-coated and
BSA-coated GO is fairly resistant to HRP-mediated biodegrada-
tion when compared to non-functionalized GO. In order to obtain
functionalized GO that can still undergo enzymatic degradation,
the authors conjugated PEG to GO via a cleavable disulfide bond,
obtaining GO-SS-PEG with negligible toxicity and considerable
degradability.170 This study thus points toward a safe-by-design
approach that also takes degradability into account. In fact, for drug
delivery applications, it may be important to control the
biodegradation of carbon-based nanomaterials both temporally
and spatially (i.e., degradation at the right time and at the right
place) and future efforts in this area should take into account the
deve l opmen t o f nanomed i c i ne vec t o r s t ha t a r e
degradable-on-demand.136 For some other emerging biomedical
applications, including in the field of regenerative medicine, rapid
degradation of the nanomaterial in question may not be desirable;
for instance in the case of CNTs as scaffolds for neurons in spinal
cord injury or graphene as an artificial retina (discussed above).
Concluding remarks
In synopsis, one may conclude that carbon-based nanomaterials
show tremendous promise as drug or gene delivery vehicles and/or
imaging agents, and as biosensors, in diverse areas of medicine,
although there is certainly a preponderance to date of studies on
cancer. In addition, there is emerging evidence for potential
applications of carbon-based nanomaterials in regenerative medi-
cine. However, as we have discussed at length in the present review,
studies on the biocompatibility, in vivo biodistribution, bio-corona
347K. Bhattacharya et al / Nanomedicine: Nanotechnology, Biology, and Medicine 12 (2016) 333–351formation, and biodegradation are necessary in order to translate
these promising nanomaterials into the realm of clinical medicine. In
fact, these various aspects of nanomaterial behavior in a living
system are intimately entwined: the bio-corona has been shown to
dictate biodistribution and may also impact on cellular recognition
and biodegradation, which is relevant for the safety or biocompat-
ibility of the material. Moreover, a detailed understanding of how
these nanomaterials interact with the immune system is of critical
importance. Indeed, coronation and degradation are directly
connected to the role of the immune system in defending the body
from foreign intrusion, and it can be argued that carbon-based
nanomaterials are ‘sensed’ as pathogens by immune-competent
cells.9 Careful engineering of nanomaterials is needed tomitigate the
potential toxicity of the material while retaining its useful properties,
thereby allowing for the navigation of various compartments in the
body and the timely execution of the intended function(s) at the
desired location(s). In other words, one should take care not to throw
out the baby with the bathwater. This is, in essence, the meaning of
safe-by-design.171,172 With this in mind, one may anticipate many
exciting discoveries and novel applications of the carbon-based
nanomaterials in the years to come.
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